Achaogen Inc (NASDAQ:AKAO)’s share price dropped 12.4% during trading on Tuesday . The stock traded as low as $1.36 and last traded at $1.48. Approximately 1,767,867 shares changed hands during mid-day trading, a decline of 39% from the average daily volume of 2,875,493 shares. The stock had previously closed at $1.69.
AKAO has been the subject of several analyst reports. Stifel Nicolaus cut shares of Achaogen from a “buy” rating to a “hold” rating in a research report on Friday, November 9th. Gabelli cut shares of Achaogen from a “buy” rating to a “hold” rating in a research report on Friday, November 9th. Cowen cut shares of Achaogen from an “outperform” rating to a “market perform” rating in a research report on Friday, November 9th. ValuEngine cut shares of Achaogen from a “hold” rating to a “sell” rating in a research report on Monday, December 17th. Finally, HC Wainwright restated a “neutral” rating and issued a $3.00 target price (down from $19.00) on shares of Achaogen in a research report on Monday, November 12th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $9.25.
The firm has a market cap of $77.94 million, a PE ratio of -0.47 and a beta of 0.83. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.52 and a current ratio of 2.54.
Achaogen (NASDAQ:AKAO) last announced its quarterly earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.88) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.96) by $0.08. The company had revenue of $2.00 million for the quarter, compared to analyst estimates of $3.80 million. Achaogen had a negative net margin of 2,045.86% and a negative return on equity of 214.74%. On average, equities analysts predict that Achaogen Inc will post -3.78 EPS for the current year.
In related news, major shareholder Robert W. Duggan purchased 22,431 shares of the firm’s stock in a transaction that occurred on Friday, December 7th. The shares were bought at an average cost of $1.40 per share, with a total value of $31,403.40. Following the acquisition, the insider now owns 8,443,961 shares of the company’s stock, valued at approximately $11,821,545.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Robert W. Duggan purchased 80,175 shares of the firm’s stock in a transaction that occurred on Friday, November 23rd. The shares were bought at an average cost of $1.89 per share, for a total transaction of $151,530.75. Following the completion of the acquisition, the insider now directly owns 8,343,945 shares in the company, valued at approximately $15,770,056.05. The disclosure for this purchase can be found here. Insiders have purchased a total of 1,008,362 shares of company stock worth $1,677,078 over the last ninety days. 7.80% of the stock is currently owned by insiders.
Institutional investors have recently made changes to their positions in the stock. Granahan Investment Management Inc. MA bought a new stake in shares of Achaogen during the 2nd quarter valued at approximately $1,220,000. Point72 Asset Management L.P. bought a new stake in Achaogen during the 3rd quarter worth approximately $399,000. Gabelli Funds LLC grew its holdings in Achaogen by 48.7% during the 3rd quarter. Gabelli Funds LLC now owns 306,900 shares of the biopharmaceutical company’s stock worth $1,225,000 after acquiring an additional 100,500 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Achaogen by 2,745.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 294,768 shares of the biopharmaceutical company’s stock worth $1,176,000 after acquiring an additional 284,407 shares during the last quarter. Finally, Paloma Partners Management Co bought a new stake in Achaogen during the 3rd quarter worth approximately $174,000. 45.59% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: This piece of content was reported by Enterprise Leader and is the property of of Enterprise Leader. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://theenterpriseleader.com/2019/01/08/achaogen-akao-stock-price-down-12-4.html.
About Achaogen (NASDAQ:AKAO)
Achaogen, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of antibacterial treatments for multi-drug resistant (MDR) gram-negative infections. It offers Plazomicin to treat bacterial illness, such as complicated urinary tract infection, blood stream infections, and other infections due to MDR Enterobacteriaceae.
Recommended Story: How to calculate the annual rate of depreciation
Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.